Enhanced TH 17 Responses in Patients with IL10 Receptor Deficiency and Infantile-onset IBD

Inflammatory Bowel Diseases

Volumn 23, Issue 11, 2017, Pages 1950-1961

  Shouval, Dror S ^a,b,c,d   Konnikova, Liza ^c,d,e,f   Griffith, Alexandra E ^c,d   Wall, Sarah M ^c,d   Biswas, Amlan ^c,d,f   Werner, Lael ^a,b,d   Nunberg, Moran ^a,b,d   Kammermeier, Jochen ^g   Goettel, Jeremy A ^c,d,f   Anand, Rajsavi ^c,d   Chen, Hannah ^h   Weiss, Batia ^a,b,d   Li, Jian ⁱ   Loizides, Anthony ^d,j   Yerushalmi, Baruch ^d,k   Yanagi, Tadahiro ^d,l   Beier, Rita ^d,m   Conklin, Laurie S ^d,n   Ebens, Christen L ^d,o   Santos, Fernanda G M S ^d,p   Sherlock, Mary ^d,q   Goldsmith, Jeffery D ^c,f   Kotlarz, Daniel ^c,d   Glover, Sarah C ^d,i   Shah, Neil ^g   Bousvaros, Athos ^c,d,f   Uhlig, Holm H ^d,h,s   Muise, Aleixo M ^d,t,u,v   Klein, Christoph ^d,r   Snapper, Scott B ^c,d,e,f   more..

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d VEO IBD International Consortium   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^j CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^k BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^l KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m HANNOVER MEDICAL SCHOOL   (Germany)

ⁿ CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^o UNIVERSITY OF MICHIGAN   (United States)

^p FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^q MCMASTER CHILDREN S HOSPITAL   (Canada)

^r LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^s UNIVERSITY OF OXFORD   (United Kingdom)

^t HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^u HOSPITAL FOR SICK CHILDREN   (Canada)

^v UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

IL10; IL10R; mucosal homeostasis; T cells; TH17; very early onset IBD

Indexed keywords

INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 10 RECEPTOR BETA; INTERLEUKIN 1BETA; IL10 PROTEIN, HUMAN; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; IN VITRO STUDY; INFANTILE ONSET INFLAMMATORY BOWEL DISEASE; INFLAMMATORY BOWEL DISEASE; LIMIT OF QUANTITATION; LYMPHOCYTE PROLIFERATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; TH17 CELL; CASE CONTROL STUDY; CELL PROLIFERATION; COLON; GENETICS; IMMUNOLOGY; INFANT; INTESTINE MUCOSA; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; COLON; FEMALE; HUMANS; INFANT; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTESTINAL MUCOSA; LEUKOCYTES, MONONUCLEAR; MALE; RECEPTORS, INTERLEUKIN-10; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; YOUNG ADULT;

EID: 85040733720     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000001270     Document Type: Article

References (39)

1. Shouval DS, Ouahed J, Biswas A, et al. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Adv Immunol. 2014;122:177-210.
2. Spencer SD, Di Marco F, Hooley J, et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med. 1998;187: 571-578.
3. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
4. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361: 2033-2045.
5. Glocker EO, Frede N, Perro M, et al. Infant colitis-it's in the genes. Lancet. 2010;376:1272.
6. Begue B, Verdier J, Rieux-Laucat F, et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol. 2011;106:1544-1555.
7. Pigneur B, Escher J, Elawad M, et al. Phenotypic characterization of very early-onset IBD due to mutations in the IL10, IL10 receptor alpha or beta gene: a survey of the Genius Working Group. Inflamm Bowel Dis. 2013;19: 2820-2828.
8. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology. 2012;143:347-355.
9. Engelhardt KR, Shah N, Faizura-Yeop I, et al. Clinical outcome in IL-10-and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2013;131:825-830.
10. Shouval DS, Biswas A, Goettel JA, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and antiinflammatory macrophage function. Immunity. 2014;40:706-719.
11. Zigmond E, Bernshtein B, Friedlander G, et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity. 2014;40:720-733.
12. Li B, Gurung P, Malireddi RK, et al. IL-10 engages macrophages to shift Th17 cytokine dependency and pathogenicity during T-cell-mediated colitis. Nat Commun. 2015;6:6131.
13. Li B, Alli R, Vogel P, et al. IL-10 modulates DSS-induced colitis through a macrophage-ROS-NO axis. Mucosal Immunol. 2014;7:869-878.
14. Shouval DS, Biswas A, Kang YH, et al. Interleukin 1beta mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency. Gastroenterology. 2016;151:1100-1104.
15. Murai M, Turovskaya O, Kim G, et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol. 2009;10:1178-1184.
16. Chaudhry A, Samstein RM, Treuting P, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011;34:566-578.
17. Huber S, Gagliani N, Esplugues E, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity. 2011;34:554-565.
18. Kamanaka M, Huber S, Zenewicz LA, et al. Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med. 2011;208: 1027-1040.
19. Wang F, Flanagan J, Su N, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14: 22-29.
20. Heindl M, Handel N, Ngeow J, et al. Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology. 2012;142:1093-1096 e6.
21. Neven B, Mamessier E, Bruneau J, et al. A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood. 2013;122: 3713-3722.
22. Ciofani M, Madar A, Galan C, et al. A validated regulatory network for Th17 cell specification. Cell. 2012;151:289-303.
23. Lees CW, Barrett JC, Parkes M, et al. New IBD genetics: common pathways with other diseases. Gut. 2011;60:1739-1753.
24. Chen H, Qin J, Wei P, et al. Effects of leukotriene B4 and prostaglandin E2 on the differentiation of murine Foxp3+ T regulatory cells and Th17 cells. Prostaglandins Leukot Essent Fatty Acids. 2009;80: 195-200.
25. Tanaka S, Suto A, Iwamoto T, et al. Sox5 and c-Maf cooperatively induce Th17 cell differentiation via RORgammat induction as downstream targets of Stat3. J Exp Med. 2014;211:1857-1874.
26. Yang XP, Albrecht U, Zakowski V, et al. Dual function of interleukin-1beta for the regulation of interleukin-6-induced suppressor of cytokine signaling 3 expression. J Biol Chem. 2004;279:45279-45289.
27. Holmen N, Lundgren A, Lundin S, et al. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis. 2006;12:447-456.
28. Li L, Kim J, Boussiotis VA. IL-1beta-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells. J Immunol. 2010;185:4148-4153.
29. Valmori D, Raffin C, Raimbaud I, et al. Human RORgammat+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors. Proc Natl Acad Sci U S A. 2010;107: 19402-19407.
30. Deknuydt F, Bioley G, Valmori D, et al. IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol. 2009;131:298-307.
31. Mishima Y, Liu B, Hansen JJ, et al. Resident bacteria-stimulated IL-10-secreting B cells ameliorate T cell-mediated colitis by inducing Tr-1 cells that require IL-27-signaling. Cell Mol Gastroenterol Hepatol. 2015;1: 295-310.
32. Heo YJ, Joo YB, Oh HJ, et al. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. Immunol Lett. 2010;127:150-156.
33. Ciccia F, Accardo-Palumbo A, Giardina A, et al. Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response. Arthritis Rheum. 2010;62:3625-3634.
34. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329-342.
35. Hsu P, Santner-Nanan B, Hu M, et al. IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1. J Immunol. 2015;195:3665-3674.
36. Moran CJ, Walters TD, Guo CH, et al. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis. 2013; 19:115-123.
37. Hovhannisyan Z, Treatman J, Littman DR, et al. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology. 2011; 140:957-965.
38. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367:1519-1528.
39. Sandborn W, Gasink C, Blank M, et al. O-001 a multicenter, doubleblind, placebo-controlled Phase3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohn's disease refractory to anti-TFNalpha: UNITI-1. Inflamm Bowel Dis. 2016;22(suppl 1):S1.